Show simple item record

dc.contributor.authorMullen, Carrie
dc.contributor.authorWhalley, Benjamin J
dc.contributor.authorSchifano, Fabrizio
dc.contributor.authorBaker, Julien S
dc.date.accessioned2020-02-19T01:17:40Z
dc.date.available2020-02-19T01:17:40Z
dc.date.issued2020-05
dc.identifier.citationMullen , C , Whalley , B J , Schifano , F & Baker , J S 2020 , ' Anabolic androgenic steroid abuse in the United Kingdom: An update ' , British Journal of Pharmacology , vol. 177 , no. 10 , pp. 2180-2198 . https://doi.org/10.1111/bph.14995
dc.identifier.issn0007-1188
dc.identifier.urihttp://hdl.handle.net/2299/22301
dc.description© 2020 The British Pharmacological Society. This is the peer reviewed version of the following article: Mullen, C, Whalley, BJ, Schifano, F, Baker, JS. Anabolic Androgenic Steroid Abuse in the United Kingdom; An Update The increasing popularity of anabolic androgenic steroids. Br J Pharmacol. 2020, which has been published in final form at https://doi.org/10.1111/bph.14995. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
dc.description.abstractAnabolic androgenic steroids (AASs) are prescribed for medical conditions related to low testosterone. Abuse of AASs has surged as they become recognised as potent image enhancement drugs. The primary goal of most abusers is to obtain a more attractive outward appearance. Abuse is complex. There are a vast range of AAS substances illegally available, the nature of their true composition is difficult to evaluate. Users follow dosing patterns which incorporate a number of different AASs, in addition to other pharmaceutical substances believed to complement the desired physical effects or manage unwanted effects. Animal work and medical case reports suggest potential to cause serious hepatotoxicity, plus possible neurotoxicity, nephrotoxicity and damage to the cardiovascular and reproductive systems. As the long-term AASs users reach maturity, further controlled experimentation, with larger sample sizes, is required. Data gathering should be directed towards the most vulnerable group of AAS users, females and adolescent boys.en
dc.format.extent19
dc.format.extent1660376
dc.language.isoeng
dc.relation.ispartofBritish Journal of Pharmacology
dc.subjectPharmacology
dc.titleAnabolic androgenic steroid abuse in the United Kingdom: An updateen
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.description.statusPeer reviewed
dc.date.embargoedUntil2021-01-28
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85081619029&partnerID=8YFLogxK
rioxxterms.versionofrecord10.1111/bph.14995
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record